MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Medical Devices & Technology (Technology)
*Driving Forces: Telemedicine,Telehealth, Mobile Health, mHealth, Virtual, Digital Health, DTx (Digital Therapeutics)
*Driving Forces: Telemedicine,Telehealth, mHealth & Home Health (Sectors)
*Driving Forces: Primary Care, Chronic Disease, Wellness, Weight Loss, Obesity, Coordinated Care
*Pioneers: Cardiology & Cardiovascular
Medical & Clinical Specialities
Diseases, Illnesses, Injury & Injuries
MRSA
Parents
Diseases, Illnesses, Injury & Injuries
Children
2011: Practice-Based Research Network Reports on Community Acquired Methicillin-Resistant Staphylococcus Aureus-MRSA ( 2011)
2014: FDA panel votes in favor of approval for Cubist's new MRSA drug
2017: VA_65--65-506-18-1-030-0003 - MRSA Reagent Kits
2017: VA_65--655-18-1-039-0006 MRSA Test Kits
2017: VA_66--MRSA - Cepheid
2019: U.S. Army_MEDCOM_For the purchase of reagents for MRSA testing_Justification and Approval
Clinical trial for the company’s point-of-care diagnostic medical device for detecting methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA).
Clinical-stage biopharmaceutical company:Focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer
Clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections
Cubist’s top-selling drug is Cubicin, used to combat Methicillin-resistant Staphylococcus aureus, or MRSA.
Developing a battery-powered, pen-like device that uses cold plasma technology to sterilize and heal wounds, including those infected with drug-resistant bacteria like MRSA.
MRSA
MRSA
MRSA (methicillin-Resistant Staphylococcus Aureus ) Infection
The Cincinnati-area company is developing a low-cost, point-of-care diagnostic test for MRSA (Methicillin-resistant Staphylococcus aureus) to be sold to hospitals and physicians’ offices
The company’s first product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by MRSA.